Schering, Berlex win approval for Angeliq

Schering is preparing a mid-2006 US launch of the hormone replacement therapy Angeliq following the FDA's approval of the therapy today. Analysts said the German drug company should garner about €250 million per year from the product. Jointly owned by Schering and Berlex Laboratories, Angeliq is already available in Europe.

- read this story from AFX for more information

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.